Second Consensus Statement on Terminology, Coding and Labeling of Cellular Therapy Products

In 2005 the Boards of AABB, ASBMT, ASFA, EBMT, FACT, ICCBBA, ISBT, ISCT, JACIE, NMDP and WMDA issued a consensus statement in support of the use of ISBT 128 in the coding of hematopoietic progenitor cell and other therapeutic cell products and announced the establishment of a co-sponsored International Cellular Therapy Coding and Labeling Advisory Group.

Since that time the Advisory Group has been meeting regularly and has established a well structured terminology for hematopoietic progenitor cells which has been adopted as the formal terminology in the accreditation standards of AABB, FACT, and JACIE. In addition a number of cellular therapy laboratories have implemented the ISBT 128 Standard for coding and labeling of their products. The Asia Pacific Blood and Marrow Transplantation Group has recently joined the Advisory Group.

Recognizing:

- the need for a common and consistent means of coding and labeling for all cellular therapy products;
- the importance of globally unique identification for cellular therapy products as an essential element of effective traceability;
- the importance of an agreed common structured terminology to describe cellular therapy products;

The Boards of the above organizations:

- acknowledge the substantial progress that has been made by the Cellular Therapy Coding and Labeling Advisory Group;
- encourage cell therapy facilities to move forward with the implementation of ISBT 128 coding and labeling;
- request the Cellular Therapy Coding and Labeling Advisory Group to extend the terminology to cover non-hematopoietic cellular therapy products, working with other technical advisory groups as appropriate;
- encourage other relevant professional bodies, accreditation bodies, regulators and health authorities to support this drive for global standardization.

For further information on this initiative contact cellulartherapy@isbt128.org